← All trials
NCT03718273
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 19, 2018
- Primary completion
- Aug 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 232
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidad Complutense de MadridLead sponsor
- Universidad Complutense de MadridStudy chair
- Universidad Complutense de MadridSponsor investigator
- Universidad Carlos III MadridCollaborator
- Spanish Clinical Research NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.